About: Effects of Anticoagulants and Corticosteroids therapy in patients affected by severe COVID-19 Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effects of Anticoagulants and Corticosteroids therapy in patients affected by severe COVID-19 Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effects of Anticoagulants and Corticosteroids therapy in patients affected by severe COVID-19 Pneumonia
Creator	Arabia, Saudi Madinah, Al Hospital, Pharmacy, Al, Madinah Al, Munawarah Alharbi, Malak Alharbi, Raed Aljundi, Mahmooud Almohammadi, Ghazi Almuairfi, Zainab Alvi, Irshad Basabrain, Abdulrahman Ghalilah, Khalid Momin Sabir, Abdul
Source	MedRxiv
abstract	Background In the absence of a standard of treatment for COVID-19, the combined use of anti-inflammatory (corticosteroids and Enoxaparin) and antiviral drugs may be more effective than using either modality alone in the treatment of COVID-19. Methods Patients hospitalized between April 10th, 2020, through May 10th, 2020, who had confirmed COVID-19 infection with clinical or radiographic evidence of pneumonia, in which 65 patients have moderate COVID-19 pneumonia, and 63 patients have severe COVID-19 pneumonia. All patients received early combination therapy of anti-inflammatory (corticosteroids and Enoxaparin) and antiviral drugs. They assessed for type and duration of treatment, and days need to wean from oxygen therapy, length of stay, virus clearance time, and complication or adverse events. All patients had more than 28 days follow up after discharge from the hospital. Results Moderate COVID-19 pneumonia group were 65 patients who received Enoxaparin, antiviral drugs, empirical antibiotics for pneumonia, and standard treatment for comorbidity. Male patients were 50 (76.9 %) and female patients were 15 (23.1 %). 34 (52.3 %) patients have comorbidity, 25 (38.5%) patients have Diabetes Mellitus and 2 (3.1 %) pregnant ladies. 19 (29.2 %) patients were on low flow oxygen therapy, 3L oxygen or less to maintain oxygen saturation more than 92%. All patients discharged home with no major or minor bleeding complications or significant complications. Severe COVID-19 pneumonia group were 63 patients who received methylprednisolone, enoxaparin, antiviral drugs, empirical antibiotics for pneumonia, and standard treatment for comorbidity. Male patients were 55 (87.3 %) and female patients were 8 (12.7 %). 37 (58.7 %) patients have comorbidity, and 24 (38.1%) patients have Diabetes Mellitus. 32 (50.8 %) patients were on low flow oxygen therapy, 4-9L oxygen, and 31 (49.2 %) patients were on low flow oxygen therapy, 10L oxygen or more, including 12 patients on a non-rebreathing mask. Patients received methylprednisolone were 37 (58.7 %) for 3 days, 16 (25.4 %) for 5 days and 10 (15.9 %) for more than 5 days. Sixty-two patients discharged home with one patient had a long stay, and the other two transferred to ICU. One long-stay patient transferred to ICU on low flow oxygen therapy. Conclusion Early use of a combined anti-inflammatory (corticosteroids and Enoxaparin) and antiviral drugs treatment in patients with moderate to severe COVID-19 pneumonia prevent complications of the disease and improve clinical outcomes.
has issue date	2020-06-29(xsd:dateTime)
bibo:doi	10.1101/2020.06.22.20134957
has license	medrxiv
sha1sum (hex)	1a33a8654b34b5ca7712f01f04c1d96e5663ad35
schema:url	https://doi.org/10.1101/2020.06.22.20134957
resource representing a document's title	Effects of Anticoagulants and Corticosteroids therapy in patients affected by severe COVID-19 Pneumonia
resource representing a document's body	covid:1a33a8654b34b5ca7712f01f04c1d96e5663ad35#body_text
is schema:about of	named entity 'antiviral drugs' named entity 'therapy' named entity 'anti-inflammatory' named entity 'COVID' named entity 'antiinflammatory' named entity 'hydroxychloroquine' named entity 'risk factor' named entity 'pathogenesis' named entity 'viral epidemic' named entity 'preprint' named entity 'Ceftriaxone' named entity 'pathogens' named entity 'mechanical ventilator' named entity 'sepsis' named entity 'oxygen therapy' named entity 'pneumonia' named entity 'Lopinavir/Ritonavir' named entity 'ICU' named entity 'emergency department' named entity 'LMWH' named entity 'hospital-acquired pneumonia' named entity 'corticosteroids' named entity 'oxygen saturation' named entity 'organ dysfunction' named entity 'infection' named entity 'ICU' named entity 'COVID' named entity 'inflammation' named entity 'virus' named entity 'influenza virus' named entity 'D-Dimer' named entity 'CC-BY-ND' named entity 'steroid' named entity 'immune functions' named entity 'steroid' named entity 'pneumonia' named entity 'RT-PCR' named entity 'preprint' named entity 'antiviral drugs' named entity 'COVID' named entity 'MRSA' named entity 'Lopinavir/Ritonavir' named entity 'azithromycin' named entity 'ICU' named entity 'Windows' named entity 'insomnia' named entity 'immune responses' named entity 'oxygen therapy' named entity 'antiviral drugs' named entity 'cytokines' named entity 'severe acute respiratory syndrome coronavirus' named entity 'Levofloxacin' named entity 'high blood pressure' named entity 'firstline' named entity 'antiviral drugs' named entity 'hypercoagulable states' named entity 'respiratory syncytial virus' named entity 'hydroxychloroquine' named entity 'sepsis' named entity 'mechanically ventilated' named entity 'critically ill' named entity 'methylprednisolone' named entity 'pneumonia' named entity 'methylprednisolone' named entity 'acute phase' named entity 'June 29' named entity 'Madinah Al Munawarah' named entity 'immune dysfunction' named entity 'COVID' named entity 'ambient air' named entity 'RT-qPCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software